Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2007 Oct 15;17(20):5537-42. Epub 2007 Aug 19.

Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation.

Author information

1
Discovery Chemistry, Pfizer Global Research & Development, Nagoya Laboratories, 5-2 Taketoyo, Aichi 470-2393, Japan. makoto.kawai@pfizer.com

Abstract

A novel potent NMDA-NR2B selective antagonist without the reactive metabolites formation issue was identified. Through this study, a close correlation between reactive metabolites formation and calculated HOMO energies of parent compounds was found.

PMID:
17766107
DOI:
10.1016/j.bmcl.2007.08.033
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center